Return to site

Trek Therapeutics’ Compassionate Drug Use Policy

Robert Hindes MD

A graduate of Rutgers Medical School, Robert Hindes, MD, previously served as medical director of the clinical teaching unit at Danbury Hospital in Danbury, Connecticut, group director of virology, global clinical research at Bristol-Myers Squibb, and vice president of clinical development at Pharmasset, Inc. Currently, Robert Hindes, MD, serves as the chief medical officer and cofounder of Trek Therapeutics.

A public benefit company, Trek Therapeutics has worked to develop innovative and affordable drug regimens for viral diseases since its founding in 2014. The firm, which expects to launch an affordable best-in-class treatment for hepatitis C by 2022, currently maintains a portfolio of five pharmaceuticals. These investigative drugs are not currently available for compassionate use, but the company will seek opportunities to create access for untreated patients as its clinical trials progress.
Compassionate drug use refers to the clinical applications of unapproved pharmaceuticals in cases of severely ill patients. These drugs are known as investigative drugs and are typically only administered to patients participating in a clinical trial. However, patients that have no other treatments available to them can work with their doctors to request compassionate-use drugs from a pharmaceutical firm. To do so, the pharmaceutical firm must obtain FDA approval before any drug can be administered. In the case of hepatitis C, curative treatments are already available, but most patients remain untreated because existing treatments are unaffordable or otherwise inaccessible.

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly